$RCUS

William Blair initiated coverage on Arcus Biosciences (NYSE:RCUS) with an Outperform rating and $50 price target, implying 119% upside. The clinical-stage company's lead asset, casdatifan, targets clear cell renal cell carcinoma. William Blair estimates potential 2040 sales of $10.5B, though cash burn is a concern. Analysts highlight clinical and regulatory risks. Other firms also initiated coverage with positive ratings and price targets.

Wall Street analysts made several calls: Mizuho upgraded Albemarle (ALB) citing battery storage demand, Goldman upgraded Trane (TT) with a $565 target, Morgan Stanley reiterated SpaceX (SPCX) overweight, Barclays downgraded Dell (DELL), Jefferies upgraded Brinker (EAT), Barclays initiated Alcoa (AA) and Kaiser (KALU) as overweight, JPMorgan initiated Kirby (KEX) and Arcus (RCUS) as overweight, and reiterated Apple (AAPL) overweight.

Wedbush analyst Robert Driscoll maintained an Outperform rating and $43 price target for Arcus Biosciences (RCUS). The company is developing cancer treatments, with its lead drug Casdatifan in trials for renal cell carcinoma. Arcus plans to present new data on October 20, 2026.

Arcus Biosciences (RCUS) shares rose 3.4% after TD Cowen initiated coverage with a Buy rating. Analyst Tara Bancroft cited potential for casdatifan to lead in renal cell carcinoma treatment, noting its progression-free survival advantage over Welireg. Bancroft highlighted data that could derisk Phase III trials and position casdatifan in the $10B+ market.

Arcus Biosciences (NYSE:RCUS) and Summit Therapeutics (NASDAQ:SMMT) announced a clinical trial collaboration combining Arcus’s casdatifan (HIF-2α inhibitor) with Summit’s ivonescimab (PD-1/VEGF bispecific) for clear cell renal cell carcinoma, including first-line metastatic disease. Summit supplies ivonescimab; Arcus runs the ARC-20 cohort. Initial data expected mid-2027. RCUS reported Q2 2026 revenue of $41M and net loss of $91M, with $775M cash.

Arcus Biosciences, Inc. (RCUS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update August 5, 2026 • Arcus executes on strategy to establish casdatifan as a backbone therapy across each line of treatment for clear cell renal cell carcinoma (ccRCC), includi

HC Wainwright raised its Arcus Biosciences (RCUS) price forecast 33%, from $32 to $45, citing Arcus’ push to position casdatifan in first-line clear cell renal cell carcinoma. Arcus said it is enrolling a Phase 1/1b ARC-20 cohort to support a Phase 3 start by year-end 2026. The model assumes about $2.2B peak unadjusted 1L revenues.

Jaen Juan C. (President) sold 68,569 indirectly-held shares of Arcus Biosciences, Inc. (RCUS) at an average of $29.63 ($28.61–$30.05, $2.03M total) across 3 trades over 2026-07-09 to 2026-07-10 under a Rule 10b5-1 trading plan.

Jaen Juan C. (President) sold 31,431 indirectly-held shares of Arcus Biosciences, Inc. (RCUS) at an average of $27.92 ($27.03–$29.66, $0.88M total) across 4 trades over 2026-06-22 to 2026-06-24 under a Rule 10b5-1 trading plan.

Arcus Biosciences, Inc. (RCUS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. rcus-20260611 false 0001724521 0001724521 2026-06-11 2026-06-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________________________________________ FORM 8-K ________________________________________________________ CURRENT REPORT Pursua